Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xencor has received a milestone payment from Boehringer Ingelheim, triggered by the regulatory submission for Phase 1 clinical trials of a novel monoclonal antibody that was optimised using one of Xencor’s XmAb Fc (constant fragment) technology platforms under a technology license agreement entered in February 2007.
Subscribe to our email newsletter
Xencor claims that a proprietary suite of XmAb Fc variants allows the selective improvement of antibody cytotoxic properties by enhancing antibody-dependent cell cytotoxicity (ADCC), phagocytosis and/or complement activation.
As part of its license agreement, Boehringer Ingelheim has also exercised an option to utilize XmAb High ADCC technology for a second discovery program in oncology against an undisclosed target.
Xencor CEO Bassil Dahiyat said that their partners continue to move Fc engineered antibodies into the clinic optimised for heightened potency and convenient dosing, important attributes when differentiating from existing agents and biosimilars.
"Our XmAb technology is also fueling Xencor’s internal pipeline, which includes several optimised antibodies for both oncology and autoimmune diseases," Dahiyat said.